How to Conduct a Remote Factory Audit of a Chinese Medical Silicone Manufacturer

For most medical device procurement professionals outside China, an on-site factory audit of a Chinese silicone supplier involves a 10–14 hour flight, significant travel cost, and 3–5 days away from the office. For smaller companies, early-stage supplier evaluations, or routine surveillance audits of established suppliers, this investment is difficult to justify — particularly when the audit may reveal that the supplier does not meet qualification requirements.

The good news: a well-structured remote factory audit can verify the majority of what an on-site audit reveals — and in some respects, the preparation discipline required for a remote audit produces more rigorous documentation review than a rushed on-site visit.

The bad news: remote audits have genuine limitations. There are things you simply cannot verify remotely — the smell of a cleanroom that has not been properly maintained, the body language of a quality manager who is concealing a problem, the actual condition of equipment that looks fine on a video call. Understanding what remote audits can and cannot verify is the foundation of using them effectively.

This guide gives you a complete, practical framework for conducting remote factory audits of Chinese medical silicone manufacturers — including a structured 2-hour audit agenda, a pre-audit document request list, specific questions for each audit area, red flags to watch for, and guidance on when to escalate to a third-party on-site audit.

Part 1: What Remote Audits Can and Cannot Verify

Before designing your remote audit protocol, be clear about its capabilities and limitations.

What Remote Audits Can Verify Effectively

The Fundamental Limitation of Remote Audits

A remote audit reviews what the supplier chooses to show you. An on-site audit allows you to observe what the supplier actually does. This distinction matters most for:

• Unannounced elements: On-site audits can include unannounced visits to production areas. Remote audits are inherently announced and prepared.

• Physical evidence: You cannot pick up a batch record and examine it for signs of backdating. You cannot open a cabinet to see what is actually stored there.

• Personnel behavior: Operators who know they are being observed on video will behave differently than those observed in person.

Practical implication: Remote audits are appropriate for initial supplier screening, routine surveillance of established suppliers, and documentation-focused qualification audits. For first-time qualification of a supplier for a critical, high-risk component, a remote audit should be followed by an on-site audit (your own team or a third party) before final approval.

Part 2: Pre-Audit Preparation — The Document Request Package

The most valuable part of a remote audit happens before the video call. A comprehensive pre-audit document review allows you to focus the live session on verification, clarification, and observation — rather than spending the call reading documents.

Request the following documents at least 2 weeks before the scheduled audit date. A supplier's willingness and ability to provide complete, organized documentation within this timeframe is itself an audit finding.

Mandatory Pre-Audit Documents

Category 1: Certifications and Registrations

• Current ISO 13485 certificate (full document, not just front page) — with scope statement

• ISO 13485 surveillance audit report (most recent — within 12 months)

• FDA establishment registration confirmation (printout from FDA database, or registration number for independent verification)

• CE Declaration of Conformity for relevant product categories (if applicable)

• Any other market-specific registrations (NMPA, Health Canada, TGA, etc.)

Category 2: Biocompatibility and Material Documentation

• USP Class VI test report — full report (not certificate), showing actual test data, compound lot tested, testing laboratory, and test date

• ISO 10993-5 cytotoxicity test report — full report with cell viability data

• ISO 10993-10 sensitization and irritation test report (if applicable to your product)

• FDA 21 CFR 177.2600 compliance statement

• Material Safety Data Sheet (SDS/MSDS) for the silicone compound

• Technical Data Sheet (TDS) for the silicone compound — showing curing system (platinum or peroxide)

• Raw material certificates for PDMS and key additives (confirming medical-grade specification)

Category 3: Quality Management System Documentation

• Quality Manual (or equivalent top-level QMS document)

• Organizational chart showing quality function reporting structure

• List of controlled procedures relevant to your product (document numbers and revision levels — not full text)

• Internal audit schedule and most recent internal audit report (summary)

• Management review meeting minutes (most recent — within 12 months)

• CAPA log (summary — open and closed CAPAs from past 24 months)

• Customer complaint log (summary — past 24 months)

• Supplier qualification list (approved supplier list — summary)

Category 4: Product-Specific Documentation

• Sample Certificate of Analysis (CoA) for a recent production lot of your product type

• Sample batch record (redacted for confidentiality if needed) showing traceability structure

• Inspection and test plan for your product type

• Dimensional tolerance specification and measurement system used

• Cleanroom classification documentation and most recent environmental monitoring report

Category 5: Manufacturing Capability

• Equipment list for extrusion lines (or molding presses) — make, model, year, capacity

• Calibration schedule and most recent calibration records for critical measurement equipment (laser micrometers, Shore A durometers, tensile testers)

• Production capacity statement — current utilization and maximum capacity for your product type

Supplier response quality is an audit finding. A supplier that provides complete, well-organized documentation within the requested timeframe demonstrates a mature quality system. A supplier that provides incomplete documentation, substitutes certificates for test reports, or requires multiple follow-up requests is showing you their quality culture before the audit even begins.

Part 3: Certificate Verification — Do This Before the Audit Call

Never accept a certificate at face value. Before the audit call, independently verify every certificate the supplier provides.

ISO 13485 Certificate Verification

Step 1: Identify the issuing certification body from the certificate (BSI, TÜV Rheinland, TÜV SÜD, SGS, Bureau Veritas, Intertek, DNV, Lloyd's Register, etc.)

Step 2: Go to the certification body's online certificate registry:

• BSI: bsigroup.com/en-GB/validate-bsi-issued-certificates/

• TÜV Rheinland: certipedia.com

• TÜV SÜD: tuvsud.com/certificate-finder

• SGS: sgs.com/certificate-verification

• Bureau Veritas: certificateverification.bureauveritas.com

Step 3: Search by certificate number or company name. Verify:

• Certificate is current (not expired)

• Company name matches the supplier you are auditing (not a parent company or related entity)

• Facility address matches the manufacturing location (not just a head office)

• Scope explicitly covers medical silicone tubing or medical device manufacturing — not just "rubber products" or "industrial silicone"

• No suspensions or conditions noted on the certificate

Red flag: A certificate that cannot be verified in the issuing body's registry is either expired, suspended, or fraudulent. This is an immediate disqualification.

FDA Establishment Registration Verification

Step 1: Go to: accessdata.fda.gov/scripts/cdrh/cfdocs/cfrl/rl.cfm

Step 2: Search by the supplier's company name or registration number.

Step 3: Verify:

• Registration is active (not expired or cancelled)

• Facility address matches the manufacturing location

• Product codes listed are relevant to your product type

Note: FDA establishment registration for a medical device manufacturer is an annual requirement. A lapsed registration indicates the supplier has not maintained their FDA compliance obligations.

Biocompatibility Test Report Verification

Step 1: Identify the testing laboratory from the test report header.

Step 2: Verify the laboratory's accreditation:

• For ISO 10993 testing: verify ISO 17025 accreditation for biological testing

• For USP Class VI testing: verify the laboratory is recognized for USP testing (many are A2LA or NVLAP accredited)

• Search A2LA directory: a2la.org/search/

• Search ILAC MRA partners: ilac.org/ilac-mra-and-signatories/

Step 3: Verify the report content:

• Compound lot number is specified — not just "medical silicone compound"

• Test date is within the past 5 years (ISO 10993 data older than 5 years requires justification)

• Actual test data is present (cell viability percentages, animal observation records) — not just a pass/fail summary

• Extraction conditions are specified (extraction ratio, temperature, duration)

• Test method references are cited (e.g., ISO 10993-5:2009, USP <87>, USP <88>)

Part 4: The 2-Hour Remote Audit Agenda

Structure your remote audit as a focused 2-hour session. Longer sessions lose focus; shorter sessions cannot cover the necessary ground. The following agenda is designed for a first-time qualification audit of a medical silicone tubing or molded component supplier.

Technology setup: Use a platform that supports screen sharing (for document review) and camera switching (for facility tour). Zoom, Microsoft Teams, and Google Meet all work. Request that the supplier have two devices available — one for the main call (document sharing, personnel interviews) and one mobile device for the facility tour (camera tour of production areas).

Participants (supplier side): Quality Manager (mandatory), Production Manager (mandatory), Sales/Account Manager (optional). The quality manager should be the primary speaker for quality system questions.

Participants (your side): Lead auditor (quality engineer or procurement manager), technical reviewer (applications engineer if available), note-taker.

Segment 1: Opening and Company Overview (15 minutes)

Objective: Establish context, verify organizational structure, assess quality culture.

Questions:

• "Please walk us through your organizational chart — specifically the quality function. Who does the Quality Manager report to?"(Quality should report to senior management, not to production. Quality reporting to production is a structural conflict of interest.)

• "How many employees do you have dedicated to quality functions (QC inspection, QA, regulatory affairs)? What percentage of total headcount is that?"(For a medical silicone manufacturer, quality headcount below 8–10% of total is a concern.)

• "What percentage of your production is for medical device applications versus industrial or food-grade applications?"(A supplier where medical is a small fraction of business may not prioritize medical quality requirements.)

• "Can you describe your top three customer relationships — not by name, but by geography and product type?"(Establishes market credibility and customer base quality.)

• "Have you had any ISO 13485 non-conformances, FDA observations, or customer quality escapes in the past 24 months? If so, please describe the most significant one and how it was resolved."(How a supplier describes past problems reveals more about quality culture than a clean record.)

Documents to review during this segment:

• Organizational chart (pre-submitted)

• ISO 13485 certificate (verify scope on screen)

Segment 2: Quality Management System Deep Dive (25 minutes)

Objective: Verify that the QMS is genuinely implemented, not just documented.

Questions:

On document control:

• "Can you show me your document control system — specifically, how a controlled procedure is identified as current versus obsolete?"(Request a live screen share of their document management system. A paper-based system is not disqualifying, but must show clear revision control.)

• "If I asked you to retrieve the current version of your extrusion process specification for medical tubing right now, how long would that take?"(Should be less than 2 minutes. Longer indicates document control problems.)

On CAPA:

• "Please open your CAPA log and walk me through the three most recently closed CAPAs."(Look for: clear root cause identification, appropriate corrective actions, evidence of effectiveness verification. Superficial root causes like "operator error" without systemic correction are a red flag.)

• "What is your average time to close a CAPA from opening to effectiveness verification?"(Greater than 90 days for routine CAPAs suggests a backlogged or under-resourced quality system.)

On internal audits:

• "When was your last internal audit of the extrusion/molding production area? What findings were identified?" (Request to see the audit report summary. Zero findings in an internal audit is itself a finding — it suggests the audit was not rigorous.)

On management review:

• "Can you show me the agenda and key outputs from your most recent management review meeting?" (Management review must include quality metrics, customer complaints, CAPA status, and resource adequacy. A management review that does not discuss these topics is a QMS non-conformance.)

On supplier control:

• "How do you qualify your PDMS raw material suppliers? Can you show me your approved supplier list and the qualification criteria?" (A medical silicone manufacturer must have a documented supplier qualification process for critical raw materials. Purchasing from unqualified suppliers is a significant risk.)

Documents to review during this segment:

• CAPA log (live screen share)

• Most recent internal audit report (live screen share)

• Management review minutes (live screen share)

Segment 3: Manufacturing Capability and Process Controls (30 minutes)

Objective: Verify that production processes are controlled, monitored, and capable of producing product to your specification.

Questions:

On cleanroom:

• "Please show us your cleanroom on the mobile camera. Can you walk us through the gowning area, the airlock, and the production floor?"(Observe: gowning protocol, air pressure differential indicators, cleanliness of surfaces, segregation of medical vs. non-medical production, personnel PPE compliance.)

• "What is your cleanroom classification, and can you show us your most recent environmental monitoring report — particle counts and microbial monitoring?"(ISO Class 7: ≤352,000 particles/m³ at 0.5μm. ISO Class 8: ≤3,520,000 particles/m³ at 0.5μm. Request the actual monitoring data, not just the classification claim.)

• "How frequently do you conduct environmental monitoring, and what is your action limit for particle counts?"(Monthly minimum for ISO Class 8; weekly or continuous for ISO Class 7. No defined action limit suggests monitoring is compliance theater rather than process control.)

On dimensional control:

• "Can you show us your extrusion line on the mobile camera? Specifically, can you show us the laser micrometer and how it is positioned relative to the extrusion die?"(Closed-loop laser micrometer monitoring is the standard for precision medical tubing. Manual spot-checking with a micrometer is insufficient for ±0.05mm tolerance.)

• "What happens when the laser micrometer detects an out-of-tolerance reading? Can you walk us through the response procedure?"(Should trigger an automatic alarm, production stop or diversion, investigation, and documented disposition of product produced during the out-of-tolerance period.)

• "How do you validate that your measurement system is capable of detecting the tolerances you are claiming? Do you conduct Gauge R&R studies?"(Gauge R&R is a measurement system analysis that verifies the measurement system's precision relative to the tolerance. Its absence for precision medical tubing is a gap.)

On material traceability:

• "Can you demonstrate lot traceability for a finished product? Starting from a finished goods lot number, can you trace back to the raw material batch?"(Request a live demonstration — not a description. The supplier should be able to pull up the batch record and show the raw material lot numbers within 5 minutes.)

• "How do you prevent mix-up between medical-grade and industrial-grade silicone compound in your production facility?"(Physical segregation — separate storage areas, different colored bins, dedicated equipment — is the standard. Relying on labeling alone is insufficient.)

On sterilization (if applicable):

• "Which sterilization method do you use for sterile products, and who is your contract sterilization partner?"(Verify the sterilization partner is a recognized contract sterilizer — Sterigenics, Sotera Health, BGS Beta-Gamma-Service, etc.)

• "Can you provide the most recent EtO residuals test report (ISO 10993-7) for a sterile product lot?"(Should be lot-specific or periodic — not a one-time validation report from years ago.)

Documents to review during this segment:

• Environmental monitoring report (live screen share)

• Sample batch record showing traceability (live screen share)

• Calibration record for laser micrometer (live screen share)

Segment 4: Product-Specific Documentation Review (25 minutes)

Objective: Verify that the documentation package for your specific product is complete, current, and adequate for your regulatory submission.

Questions:

• "Can you pull up the Certificate of Analysis for the most recent production lot of [your product type]? Walk us through each parameter and the acceptance criteria."(The CoA should show actual measured values — not just "pass" — for Shore A hardness, dimensional measurements, and any other specified parameters.)

• "The ISO 10993-5 test report you submitted was conducted on [compound name/lot]. Is this the same compound currently used for production? When was the compound formulation last changed?"(Biocompatibility documentation must correspond to the compound currently in production. A formulation change since the test report was issued requires re-evaluation.)

• "For a customer submitting a 510(k) to FDA, what documentation can you provide to support the biocompatibility section of the submission?"(Should include: ISO 10993-5 cytotoxicity report, USP Class VI report, ISO 10993-10 report if applicable, FDA 21 CFR 177.2600 compliance statement, and material composition information.)

• "If we place a production order today, what lot-specific documentation will ship with each lot?"(Minimum: lot-specific CoA with actual measured values, material certificate, and traceability to raw material batch.)

• "What is your change control procedure? If you change your PDMS supplier or compound formulation, how and when would you notify us?"(Should have a documented change control procedure with customer notification before implementation — not after. Request to see the change control procedure document.)

Documents to review during this segment:

• Sample CoA (live screen share of actual lot CoA)

• ISO 10993-5 test report (verify compound lot matches current production)

• Change control procedure (live screen share)

Segment 5: Closing — Red Flags, Commitments, and Next Steps (25 minutes)

Objective: Clarify any concerns identified during the audit, establish commitments, and agree on next steps.

Structure:

1. Summarize observations — share your preliminary findings (positive and negative) with the supplier in real time. This gives them the opportunity to provide clarification and demonstrates audit transparency.

2. Request corrective actions for any gaps — for each gap identified, request a written response within 10 business days describing the root cause and planned corrective action.

3. Agree on documentation follow-up — list any documents that were not available during the audit and set a deadline for provision (typically 5 business days).

4. Discuss next steps — if the audit is satisfactory, agree on the sample request and qualification timeline. If significant gaps were identified, agree on a re-audit date after corrective actions are implemented.

Part 5: Red Flags — What to Watch For During a Remote Audit

Some findings are immediately disqualifying. Others are significant concerns that require corrective action before qualification. Know the difference.

Immediate Disqualifiers

Certificate cannot be verified in the issuing body's registry — expired, suspended, or fraudulent

ISO 13485 scope does not cover medical silicone tubing or medical device manufacturing

Biocompatibility test reports are certificates only — no actual test data available, or the supplier cannot produce the underlying reports

Peroxide-cured compound used for products intended for patient contact or pharmaceutical fluid paths — and the supplier is unwilling or unable to supply platinum-cured

No cleanroom — medical silicone tubing produced in an open factory environment with no environmental controls

No material traceability — supplier cannot demonstrate lot-level traceability from finished product to raw material within the audit session

Resistance to audit — supplier declines to show production areas on video, refuses to share QMS documents, or becomes evasive when asked about quality escapes or CAPA history

Significant Concerns (Require Corrective Action Before Qualification)

⚠️ CAPA log shows superficial root cause analysis — "operator error" without systemic correction, or CAPAs open for >6 months without resolution

⚠️ No Gauge R&R or measurement system validation for critical dimensional measurements

⚠️ Environmental monitoring data is incomplete — missing months, no action limits defined, or particle counts consistently near the ISO class limit

⚠️ Change control procedure does not require customer notification before raw material or process changes

⚠️ Quality reports to production rather than to senior management — structural conflict of interest

⚠️ Biocompatibility test reports are >5 years old without documented justification for continued applicability

⚠️ CoA shows nominal values only — no actual measured data for critical parameters

⚠️ Medical and industrial production not physically segregated — risk of compound mix-up

Positive Indicators

✅ Quality Manager speaks confidently and specifically about quality issues — including past problems and how they were resolved

✅ Batch records are retrievable within minutes and show clear traceability structure

✅ Environmental monitoring data shows consistent results well within ISO class limits — not just barely compliant

✅ CAPA root cause analysis goes to systemic causes — process design, training system, supplier control — not just individual operator behavior

✅ The supplier asks you questions about your application and regulatory requirements — not just about price and volume

✅ Documentation is complete, organized, and provided ahead of the requested deadline

Part 6: Post-Audit Documentation — The Audit Report

Every remote audit should produce a written audit report, regardless of outcome. The report serves three purposes: it documents your due diligence for regulatory purposes, it provides the supplier with clear feedback, and it creates a baseline for future surveillance audits.

Minimum Audit Report Contents

• Audit date, duration, and participants (names and roles)

• Audit scope (product types, QMS elements covered)

• Audit method (remote video audit via [platform])

• Documents reviewed (list with document numbers and revision levels)

• Findings summary — organized by audit segment

• Non-conformances (if any) — classified as major or minor per ISO 19011

• Observations (opportunities for improvement, not formal non-conformances)

• Positive findings — document what the supplier does well

• Overall audit conclusion — Approved / Conditionally Approved / Not Approved

• Required corrective actions — with response deadlines

• Next audit date (for approved suppliers: annual surveillance)

Audit Classification Definitions

Part 7: Third-Party Audit Options — When to Use Them

Remote audits conducted by your own team have inherent limitations. Third-party on-site audits by accredited audit firms provide independent verification that cannot be replicated remotely. Consider third-party audits in the following situations:

When Third-Party Audits Are Appropriate

• First-time qualification of a critical, high-risk component supplier — before committing to a long-term supply relationship for a life-sustaining device component

• Supplier with significant remote audit findings — when corrective actions have been submitted but you need independent verification of implementation

• Regulatory requirement — some regulatory pathways or notified bodies require on-site supplier audits as part of the technical documentation

• Supplier relationship deterioration — declining quality metrics, increasing complaints, or reduced responsiveness suggesting a quality system under stress

• Post-incident investigation — following a significant quality escape, an on-site audit provides more thorough root cause investigation than a remote session

Reputable Third-Party Audit Firms for China

Typical cost: $1,500–$3,500 per on-site audit day (travel and expenses additional for remote locations)

Lead time: 2–4 weeks from booking to audit date for standard scheduling; 1 week for expedited

Hybrid Audit Approach: Remote + Third-Party

The most cost-effective approach for international supplier qualification combines:

1. Remote audit (your team): Documentation review, QMS assessment, personnel interviews — 2 hours, low cost

2. Third-party on-site audit (audit firm): Physical facility verification, unannounced production observation, independent cleanroom verification — 1 day, $2,000–$3,500

This hybrid approach provides the thoroughness of an on-site audit at a fraction of the cost of sending your own team to China.

Part 8: Surveillance Audit Schedule — Maintaining Qualification

Qualifying a supplier is not a one-time event. ISO 13485 requires ongoing supplier monitoring, and your own quality system should define a surveillance audit schedule based on supplier risk classification.

Recommended Surveillance Audit Frequency

Annual Surveillance Audit Checklist

For established suppliers, annual surveillance audits can be condensed to 60–90 minutes focused on:

• Certificate renewal verification (ISO 13485, FDA registration)

• CAPA status review — any new CAPAs since last audit?

• Customer complaint trend — increasing, stable, or decreasing?

• Key personnel changes — has the Quality Manager or Production Manager changed?

• Raw material supplier changes — any changes to PDMS or compound suppliers?

• Process or equipment changes — any changes since last audit?

• Environmental monitoring trend — any excursions in the past 12 months?

• On-time delivery performance — past 12 months data

• Review of most recent third-party audit report (if available)

Chensheng Medical: Audit-Ready, Always

At Jinan Chensheng Medical Technology Co., Ltd., we welcome supplier audits — remote or on-site — as a standard part of customer qualification. We maintain audit readiness as an ongoing operational standard, not a preparation exercise.

What we provide for remote audits:

• Complete pre-audit documentation package within 5 business days of request

• Dedicated Quality Manager and Production Manager participation

• Live video tour of our ISO Class 7 cleanroom and extrusion production areas

• Real-time batch record and traceability demonstration

• Live screen share of QMS documentation, CAPA records, and environmental monitoring data

• Independent certificate verification references for all our certifications

Our certifications — all independently verifiable:

• ISO 13485 — verify at [issuing body registry]

• FDA Establishment Registration — verify at accessdata.fda.gov

• USP Class VI — full test reports with actual data available

• ISO 10993-5, -10 — full test reports with actual data available

• FDA 21 CFR 177.2600 compliance statement

We have never declined a customer audit request. We have never received an immediate disqualifier finding in a customer audit. We view audit transparency as a competitive advantage — it is how we demonstrate that our quality claims are real, not marketing.

→ Schedule a Remote Audit→ Request Our Pre-Audit Documentation Package→ Contact Our Quality Manager Directly

Frequently Asked Questions (FAQ)

Q1: How long should a remote factory audit of a medical silicone supplier take?

A: A first-time qualification audit should be structured as a 2-hour focused session, as outlined in this guide. Shorter sessions cannot cover the necessary ground; longer sessions lose focus and productivity. Annual surveillance audits of established suppliers can be condensed to 60–90 minutes. Allow an additional 30 minutes buffer for technical difficulties, translation needs, or follow-up questions. Schedule the audit for morning China time (9:00–11:00 CST) to ensure the supplier's quality and production management are available and alert.

Q2: What technology platform works best for remote factory audits of Chinese suppliers?

A: Zoom is the most widely used and reliable platform for China-based remote audits — it has good performance on Chinese internet connections and is familiar to most Chinese manufacturers. Microsoft Teams works well but can have connectivity issues in some Chinese locations. WeChat Video Call is an acceptable backup for the facility tour portion if the primary platform has issues. Request that the supplier have a mobile device (smartphone or tablet) available for the facility tour in addition to a desktop/laptop for document sharing. Test the connection 15 minutes before the scheduled start time.

Q3: Can a remote audit satisfy ISO 13485 supplier audit requirements?

A: ISO 13485:2016 Section 7.4.1 requires that the organization evaluate and select suppliers based on their ability to supply product in accordance with requirements. It does not specify that audits must be on-site. Remote audits are widely accepted as a valid supplier evaluation method under ISO 13485, provided they are documented with the same rigor as on-site audits. Your notified body or regulatory authority may have specific guidance — check with your quality system consultant if you are uncertain about the requirements for your specific regulatory pathway.

Q4: The supplier's ISO 13485 certificate is issued by a Chinese certification body I don't recognize. Is it valid?

A: China has numerous domestic certification bodies accredited by CNAS (China National Accreditation Service for Conformity Assessment). CNAS is a signatory to the IAF MLA (International Accreditation Forum Multilateral Recognition Arrangement), which means CNAS-accredited certificates are internationally recognized in principle. However, the quality and rigor of certification bodies varies significantly. For medical device supplier qualification, we recommend prioritizing certificates from internationally recognized bodies (BSI, TÜV, SGS, Bureau Veritas, Intertek) over lesser-known domestic bodies. If a supplier holds only a domestic certification body certificate, verify the certification body's CNAS accreditation and IAF MLA status before accepting it.

Q5: What should I do if the supplier refuses to show certain areas during the facility tour?

A: A supplier's refusal to show specific areas during a remote audit is a significant red flag. Legitimate reasons for restricted access are limited (active customer confidentiality requirements for a specific production line, for example) and should be explained clearly. A blanket refusal to show production areas, cleanrooms, or material storage is not acceptable for a medical device supplier qualification audit. Document the refusal as an audit finding, classify it as a major concern, and request a written explanation. If the explanation is not satisfactory, escalate to a third-party on-site audit or decline to qualify the supplier.

Q6: How do I verify that the cleanroom shown during the video tour is actually used for my product's production?

A: This is one of the genuine limitations of remote audits. During the video tour, ask the operator to show you: (1) the product currently in production in the cleanroom (if any); (2) the batch record for the current production run; (3) the environmental monitoring log posted in the cleanroom (most cleanrooms post their most recent monitoring results). Ask the supplier to show you the physical location of the cleanroom relative to the non-cleanroom production areas — the spatial relationship should be consistent with the facility layout diagram in their pre-audit documentation. If you have concerns, request a third-party on-site audit to independently verify cleanroom usage.

Q7: We qualified a Chinese silicone supplier three years ago but have not audited them since. What should we do?

A: A three-year gap in supplier surveillance is a quality system non-conformance under ISO 13485. Prioritize scheduling a remote surveillance audit immediately. Focus the audit on changes since the original qualification: personnel changes (Quality Manager, Production Manager), raw material supplier changes, process or equipment changes, CAPA history, and customer complaint trends. Re-verify all certificates (ISO 13485, FDA registration) — both may have lapsed or been renewed with changed scope. If the supplier has undergone significant changes, treat the audit as a re-qualification rather than a surveillance audit and apply the full qualification audit agenda from this guide.

Related Articles:

• How to Choose a Reliable Medical Silicone Manufacturer in China

• Medical Silicone Supply Chain Risk Management: How to Build a Resilient Sourcing Strategy

• USP Class VI, ISO 10993, and FDA 21 CFR 177.2600: Which Certification Do You Actually Need?

• How to Choose Medical Grade Silicone Tubing: A Complete Specification and Sourcing Guide

• Sterilization Methods for Medical Silicone Products: Autoclave, EtO, Gamma, and E-Beam Compared

• Silicone Shore A Hardness Explained: How to Select the Right Durometer for Your Medical Application